Table 3.
Best overall response to therapy.
Vactosertib and Pomalidomide | |
---|---|
Response | N (%) |
Partial response | 4 (21%) |
Minimal/Marginal response | 2 (11%) |
Stable disease | 9 (47%) |
Progressive disease | 4 (21%) |
Not evaluable | 2 (11%) |
Overall Response Rate (Partial + Minimal) |
6 (32%) |
Clinical Benefit Ratio (CBR) (Stable disease + Partial + Minimal) |
15 (69%) |
Data are n (%), unless stated otherwise. Overall response to treatment (secondary endpoint) was derived according to IMWG criteria.